Abstract:
The present invention is directed to nanostructured Aprepitant compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Aprepitant according to the invention have an average particle size of less than about 200 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance characterized by significantly decreased fed/fasted effect compared to the reference and marketed drug. Aprepitant is a chemical compound that belongs to a class of drugs called substance P antagonists (SPA). It mediates its effect by acting on neurokinin 1 receptor. Aprepitant is manufactured by Merck & Co. under the brand name Emend for prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV) and for prevention of postoperative nausea and vomiting.
Abstract:
The present invention is directed to nanostructured (nanoparticulated) Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Candesartan or its pharmaceutically acceptable ester, preferable Candesartan Cilexetil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Candesartan Cilexetil is a prodrug, is hydrolyzed to Candesartan during absorption from the gastrointestinal tract. Candesartan is a selective AT1 subtype angiotensin II receptor antagonist.
Abstract:
The invention relates to a porous electrode used in an electrochemical cell, containing a carrier and/ or catalytic agent, which is characterised by that it consists of two or more layers with different average pore sizes, out of which layers the contact layer with the smallest average pore size is in contact with the membrane, and one or more supporting layers with a greater average pore size are linked to the other side of this contact layer. Furthermore, the invention relates to a procedure for the manufacturing of such electrodes and to electrochemical cells containing such electrodes.
Abstract:
The ozone generating electrolysis cell (10) according to the invention has a negative electrode (13) and an ozone generating positive electrode (16) comprising a mixture of lead dioxide and polytetrafluoroethylene (PTFE). A proton conducting solid electrolytic membrane (15) is arranged between the negative and positive electrodes (13, 16). The ozone generating electrolysis cell (10) also comprises an electrically conducting, liquid and gas permeable first electrode support (17) in contact with a side of the positive electrode (16) located opposite to the membrane (15), wherein said side of the electrode support (17) has a surface covered with a platinum-containing layer. The positive electrode (16) is made of a mixture prepared by the high-pressure compression of lead dioxide grains of colloid size and PTFE filaments having a dimension of at most 1 mm. Furthermore, the negative electrode (13) is adjoined to a side of the membrane (15) located opposite to the positive electrode (16) by a given compressing force and is formed on a surface of a porous second electrode support (12).
Abstract:
The chromatography purification system (10) for automated chromatography separation of a plurality of different components in a sample and collection the fraction of at least one target component comprises a fluid streaming unit (11), a chromatography column (12) for receiving a sample and separating the components of the sample, a sample injection valve (18) for injecting the sample, a detector (14) coupled to the chromatography column (12) for receiving the sample and outputting a signal indicating the presence of at least one component in the sample flowing through it, a waste reservoir (17), a fraction collector (16) for dispensing the collected fractions into fraction containers and a system controller (20) for controlling the operation of the fluid streaming unit (11) and the fraction collector (16). The system further comprises a selector (22) for receiving the sample from the detector (14), selecting a predetermined number of target components with a predetermined property from the at least one component of the sample, directing the fraction of the at least one selected target component to the fraction collector (16) and discharging the remaining part of the sample into the waste reservoir (17).
Abstract:
The present invention is directed to nanostructured Ezetimibe compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Ezetimibe according to the invention have an average particle size of less than about 400 nm. The stable nanostructured particles of the invention are presented by increased solubility, dissolution rate, permeability and bioequivalent or enhanced biological performance compared to the marketed drug. Ezetimibe is an anti-hyperlipidemic medication that is used to lower cholesterol levels. It acts by decreasing cholesterol absorption in the intestine.
Abstract:
The present invention is directed to nanostructured (nanoparticulated) Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Olmesartan or its pharmaceutically acceptable ester, preferable Olmesartan Medoxomil, or co-crystal according to the invention have an average particle size of less than about 500 nm. Olmesartan Medoxomil is an angiotensin II receptor antagonist used to treat high blood pressure. The prodrug Olmesartan Medoxomil is marketed worldwide by Daiichi Sankyo, Ltd. and in the United States by Daiichi Sankyo, Inc.
Abstract:
The present invention is directed to nanostructured (nanoparticulated) Telmisartan compositions, process for the preparation thereof and pharmaceutical compositions containing them. The nanoparticles of Telmisartan according to the invention have an average particle size of less than about 600 nm. Telmisartan is an angiotensin II receptor antagonist (ARB) used in the management of hypertension.
Abstract:
A flow-type laboratory scale ozonolysis apparatus (100) according to the invention comprises a reservoir (104), a feed pump (102), a mixing element (120) with two inlets and an outlet, a reactor unit (110) and a pressure-adjusting means (160), all connected into a flow path. The ozonolysis apparatus (100) further comprises an ozone source (110), as well as a dispensing valve (112) transmitting a gas stream only in a single direction and installed between the ozone source (110) and one of the inlets of the mixing element (120). The feed pump (102) of the ozonolysis apparatus (100) according to the invention is a liquid pump generating a constant volume rate, the reservoir (104) contains at least the substance, as a solute, to be subjected to the ozonolysis reaction and the reactor unit consists of first and second reactor zones differing in function from one another. In the flow path, the outlet of the first reactor zone is connected to the inlet of the second reactor zone. Furthermore, an inlet for feeding in substances is inserted into the flow path between the reactor zones, and the pressure-adjusting means (160) is installed into the flow path after the reactor unit and is provided with an electrically governed control.
Abstract:
The invention consists substantially of combinatorial, protein-marker molecule libraries, having groups that may be chemically and photochemically activated, with or without reporter groups, connected in different diversity points or spatial arrangements via side chains around a common molecular core. The invention consists furthermore of combinatorial libraries of marker units having chemically or photochemically reactive marker groups, reporter groups, and various other types of side chains attached variably to a common molecular, preferably lysine-based, structural core. The invention consists furthermore of a method for combinatorial chemical tethering, where a side chain having a terminal functional group, preferably an amino group, and to which a marker group is optionally attached, is introduced in optimal position ensuring structural diversity and protein binding effectiveness. The invention contributes to simplifying complexity of proteome in different tissues and to the identification of protein markers for diagnosis by alternating different labeling pattern in healthy and diseased tissues.